Hjem › Neuroblastom › Texas
Kliniske studier for Neuroblastom i Texas
15 studier for Neuroblastom søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- og 10 flere
RekruttererFase 3
Opp til 30 år · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
RekruttererFase 2
Opp til 22 år · Alle kjønn · Oppdatert 4. sep. 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
RekruttererFase 1/2
Opp til 26 år · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
RekruttererFase 1/2
Opp til 30 år · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
RekruttererFase 2
Alder 1 til 21 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- og 8 flere
RekruttererFase 3
365 Days – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
RekruttererFase 2
12 Months – 21 Years · Alle kjønn · Oppdatert 12. aug. 2026 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
RekruttererFase 1/2
Alder 1 til 30 · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 1 til 24 · Alle kjønn · Oppdatert 21. jul. 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
RekruttererFase 2
Alder 1 til 31 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
RekruttererObservasjonsstudie
31 Days – 99 Years · Alle kjønn · Oppdatert 23. mar. 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Rekrutterer
Opp til 17 år · Alle kjønn · Oppdatert 10. feb. 2026 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 19. sep. 2025 · NCT03294954Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.